SAHPRA Warns on Tranexamic Acid Heart Risks in South Africa

• SAHPRA has issued a warning about the potential risks of Tranexamic acid.
• Several cases worldwide have linked Tranexamic acid to serious heart problems.
• Healthcare professionals in South Africa are urged to be aware of this increased risk and advise their clients accordingly.

The warning from SAHPRA highlights the importance of monitoring medication safety in South Africa.

SAHPRA has issued a warning about the potential risks of Tranexamic acid, a medication commonly used in South Africa. The warning comes after several cases worldwide have been reported where Tranexamic acid was linked to serious heart problems. SAHPRA is urging healthcare professionals to be aware of this increased risk and advise their clients accordingly.

SAHPRA's alert is part of its ongoing regulatory activities in South Africa, which include issuing warnings about the potential risks associated with Tranexamic acid.

The warning from SAHPRA highlights the importance of monitoring medication safety in South Africa. SAHPRA has a responsibility to ensure that medications used in the country are safe for patients. In this case, the warning about Tranexamic acid is aimed at healthcare professionals who prescribe or administer the medication.

SAHPRA's role in regulating health products in South Africa demonstrates the need for vigilance in monitoring potential risks associated with medications.

The warning from SAHPRA about Tranexamic acid is a reminder that healthcare professionals have a critical role to play in ensuring patient safety. By being aware of the increased risk of serious heart problems associated with this medication, they can advise their clients accordingly and take steps to mitigate potential harm.

As SAHPRA continues to monitor the situation and provide updates, healthcare professionals should remain vigilant and stay informed about any changes or developments related to Tranexamic acid.

Healthcare professionals in South Africa should be aware of the increased risk of serious heart problems associated with Tranexamic acid and advise their clients accordingly, while also monitoring for any updates from SAHPRA or the Medicines Control Council.

Source: Original reporting via Safety Alerts